Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio's core mission is centered around revolutionizing cancer treatment by targeting extrachromosomal DNA (ecDNA), a key driver of tumor growth and drug resistance. Their primary goal is to develop innovative therapies that can effectively combat aggressive and resistant cancer forms, ultimately improving patient outcomes. By leveraging cutting-edge research and technology, Boundless Bio is dedicated to transforming the oncology landscape and providing hope to those affected by this devastating disease.

• Innovation: Boundless Bio is dedicated to pushing the boundaries of science and technology, encouraging employees to think outside the box and pursue groundbreaking solutions.
• Collaboration: Teamwork is essential to Boundless Bio's success, fostering a culture of open communication, mutual respect, and shared problem-solving.
• Patient focus: Boundless Bio is committed to improving patient outcomes, prioritizing the needs of patients and their families in all aspects of its work.
• Diversity & inclusion: Boundless Bio values diversity and inclusivity, recognizing that a variety of perspectives and experiences are essential to achieving its mission.